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Background: The aim of this substudy of the ghrelin treatment, multicenter, randomized, double-blind,
placebo-controlled trial was to investigate the effects of ghrelin administration on exercise capacity and the
underlying mechanisms in underweight patients with chronic obstructive pulmonary disease (COPD) using
cardiopulmonary exercise testing.
Methods: Twenty underweight COPD patients were randomized to pulmonary rehabilitation with intravenous
ghrelin (2 μg/kg, n = 10) or placebo (n = 10) twice daily for 3 weeks in a double-blind fashion. The primary




. Secondary outcomes included changes in exertional














Results: With incremental exercise, at peak exercise, there was a significant difference in the mean difference
(ghrelin minus placebo), i.e., treatment effect in: i) peak V
•
o2 (1.2 mL/kg/min, 95% CI: 0.2-2.3 mL/kg/min,









(−4.1, 95% CI: -8.2 to −0.1, between-group p = 0.045); iv) VD/VT (−0.04, 95% CI: -0.08 to −0.00, between-group p = 0.041);
and v) O2-pulse (0.7 mL/beat, 95% CI: 0.3 to 1.2 mL/beat, between-group p = 0.003). Additionally, repeated-measures
analysis of variance (ANOVA) indicated a significant time-course effect of ghrelin versus placebo in the peak
V
•
o2 (p = 0.025).
Conclusion: Ghrelin administration was associated with improved exertional capacity and improvements in
ventilatory-cardiac parameters.
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Chronic obstructive pulmonary disease (COPD) is a major
health issue, especially in its advanced stages. It is charac-
terized by a significant systemic deterioration, so-called
pulmonary cachexia, that affects exercise capacity, quality
of life, and survival in such patients [1-6]. Treatment
strategies targeting pulmonary cachexia have been
attempted and have provided insight into the pathogenetic
mechanisms of pulmonary cachexia [2,7].
Pulmonary rehabilitation (PR) is recommended as a
therapeutic strategy in many diseases, including cachectic
COPD [8]. However, it has been important to determine
whether cachectic COPD patients are capable of adaptive
responses to PR, because PR may partially disturb anabolic
and catabolic balance in such patients [2,9].
Ghrelin is an endogenous ligand for growth hormone
(GH) secretagogue receptor (GHSR), originally isolated
from the stomach [10]. Given that ghrelin has GH-releasing
activity, ghrelin may have beneficial effects in COPD
patients through a GH-dependent mechanism. Meanwhile,
as a GH-independent mechanism, ghrelin induces a
positive energy balance by decreasing fat utilization
[11], stimulating food intake and adiposity [12], increasing
cardiac output in healthy humans [13], and inhibiting
sympathetic nerve activity [13,14]. In an open-label pilot
study, we previously demonstrated that ghrelin may
improve walking distance and inhibit sympathetic nerve
activity in underweight COPD patients [15]. More
recently, a multicenter, randomized, double-blind, placebo-
controlled trial was conducted to investigate the efficacy
and safety of adding ghrelin to PR in underweight COPD
patients, and it showed that ghrelin administration
improved symptoms and respiratory muscle strength.
While the results were considered most likely to have
been due to ghrelin treatment, the precise mechanism that
underlies the improvement of exercise performance or
symptoms remains unclear. This study was simultaneously
conducted in a single center as part of a multicenter,
randomized, double-blind, placebo-controlled study of
underweight COPD patients [16]. The primary objective
was to investigate whether ghrelin-PR combination
treatment would improve exercise capacity. A secondary
objective was to determine whether the underlying
mechanisms of the improvements in response to ghrelin
would be associated with improvement of exertional
cardio-respiratory functions and attenuation of exertional
sympathetic nervous system activity. Some results of this
trial have been reported in abstract form [17].Methods
The protocol for this trial and Supplementary Results are
available as supporting information; see Additional file 1
(Protocol) and Additional file 2 (Supplementary Results).Subjects
The eligibility criteria for participation were as follows:
1) moderate to severe COPD (FEV1% of less than 70%
and % forced expiratory volume in one second
(FEV1) of less than 50%); 2) underweight (body mass
index (BMI) < 21 kg/m2); 3) clinically stable and
able to participate in PR; 4) between 20 and 85 years
old; and 5) signed the agreement for participation in
this study. Participants were excluded if they met
any of the following: 1) malignant tumors; 2) active
infection; 3) severe heart disease; 4) hepatic dysfunction
(serum levels of aspartate aminotransferase and alanine
aminotransferase twice the upper limit of normal or more);
5) asthma; 6) definitely or possibly pregnant; 7) change in
drug regimen within 4 weeks before participation in this
study; or 8) judged to be unable to participate in this study
by their physician, in addition to the above exclusion
criteria.
Study design
This study was a 3-week, randomized, double-blind,
placebo-controlled trial of ghrelin administration during
PR conducted at a single center (Toneyama National
Hospital) as part of a main multicenter trial [16]. To test
the primary hypothesis that ghrelin-PR combination
treatment would improve exercise capacity, recruitment
was from September 2005 until the target sample size of
18 was achieved on May 2009.
This study was approved by the ethics committee of
the National Hospital Organization Toneyama National
Hospital (approval number, 0311) and was conducted
according to the Declaration of Helsinki and Good
Clinical Practice guidelines. Written informed consent
was obtained from all subjects (in Japanese). Enrolled
patients were randomly assigned in a 1:1 ratio to receive
3-week PR with either ghrelin or placebo in a double-
blind fashion (Figure 1). The administration of ghrelin
(2 μg/kg, ghrelin solution with 10 mL saline) or placebo
was done intravenously over 30 minutes at a constant
rate and repeated twice daily for 3 weeks in hospital.
Randomization was done in our center considered as
a block in the main multicenter study [16]. The
randomization list was generated by a statistician
from Hamamatsu University School of Medicine and
maintained there until the study was finished and
unblinded. Neither the physicians nor the patients
were aware of the treatment assignments. The test
drug controller managed a copy of the randomization
list and the test drugs at the pharmacy department of
the National Hospital Organization Toneyama National
Hospital. At study completion, the randomization list was
used to confirm appropriate conduct of the trial. Patients
were tested at pre-treatment and post-treatment, i.e., Week
3. The main multicenter study [16], including this study, is
Figure 1 Outline of study design. PFT, pulmonary function test;
CPET, cardiopulmonary exercise testing.




Preparation of human ghrelin
Human ghrelin was prepared as described previously
[15,16]. In brief, ghrelin was stored in 2-mL volumes,
each containing 120 μg ghrelin. The chemical nature and
content of the human ghrelin in vials were confirmed as
described previously [15,16]. All vials were stored frozen
at −30°C until the time of preparation for administration.
Pulmonary rehabilitation (PR)
Aerobic exercise training included in the PR program
was conducted for 5 days per week, for 3 weeks, at high-
intensity targets [16]. The PR program consisted of
disease education and instruction of patients and their
families, physical therapy, i.e., conditioning including
breathing control techniques, and aerobic exercise training.
Occupational therapy was not included in the present PR
program. The aerobic exercise training sessions were
conducted as three sets (with 10-min breaks) daily, 5 days
per week, for 3 weeks, and they were performed on
electromechanically braked cycle ergometers. The initial
exercise level of each set was set for 6 min at the work rate
corresponding to 60% of the peak V
•
o2 attained on
baseline cardiopulmonary exercise testing (CPET). As
tolerated by the subject, the exercise duration wasinitially increased to 10 min. After that, the training work
rate was increased by 5 W, and then extended to the work
rate corresponding to 80% of the baseline peak V
•
o2. If the
subject found the set intolerable, it was reduced to its
previous setting. Supplemental oxygen was used if ne-
cessary to maintain an oxygen saturation >90% during
exercise training.Outcome measures
The primary outcome was change in exercise capacity,
i.e., peak oxygen uptake ðV• o2Þ. Secondary outcomes were
changes in exertional dyspnea and plasma norepinephrine
levels, as well as exertional cardio-respiratory functions:
O2-pulse (V
•
o2=HR i.e., the product of stroke volume and
the arterial-mixed venous O2 difference), physiologic dead
space/tidal volume ratio (VD/VT, i.e., the degree of
mismatching of ventilation to perfusion), ventilatory




o2 , i.e., measurement of the
ventilatory requirement for the metabolic rate), ventilatory





of the ventilatory requirement for the metabolic rate), and
inspiratory capacity (IC).Procedures
Pulmonary function measurements were done as previously
described [18]. Symptom-limited exercise tests were
conducted on an electrically-braked cycle ergometer
(CV-1000SS, Lode, Groningen, The Netherlands) using
a cardiopulmonary exercise testing (CPET) system
(Vmaxs-29C, CareFusion 207, Palm Springs, CA, USA)
[18]. Incremental testing was performed, which
consisted of 2-min increments to 10 W. Subsequent
constant-load testing, which was conducted at 70% of
the maximal incremental work rate obtained in pre-
treatment, was performed to measure the exertional
inspiratory capacity (IC) at pre-treatment and post-
treatment with the same work rate. CPET was
performed under room air conditions until subject
exhaustion. Expired gas data were measured breath-
by-breath and collected as 30-s averages at rest, during
exercise at 2-min intervals, and at end-exercise. In
addition, dyspnea and leg fatigue intensity (Borg scale)
were evaluated, and arterial blood was collected at
rest and during the last 15 s of each exercise stage
and at end-exercise. Arterial blood samples for blood
gas analyses, plasma norepinephrine, and plasma lactate
were obtained and measured as previously described [18].
Before ghrelin administration, blood samples were
also collected after 30 min of bed rest in the morning
following an overnight fast for measurement of
plasma acyl-ghrelin by radioimmunoassay, as previously
described [19].
Table 1 Patients’ baseline characteristics*
Ghrelin, n = 10 Placebo, n = 10
Age (years) 70.8 (6.4) 73.1 (5.6)
Sex (males/females) 10/0 9/1
BMI (kg/m2) 18.4 (2.4) 18.1 (2.3)
Cigarettes (pack-years) 59.1 (29.2) 64.8 (25.1)
Pulmonary function
FEV1 (L) 0.83 (0.21) 0.82 (0.23)
%FEV1 (% predicted) 32.0 (9.4) 33.3 (10.5)
FEV1/FVC (%) 41.7 (7.6) 42.4 (8.0)
VC (L) 2.54 (0.42) 2.62 (0.50)
%VC (%) 79.6 (11.0) 86.1 (15.3)
IC (L) 1.63 (0.22) 1.74 (0.38)
DLco (% predicted) 61.3 (23.8) 72.4 (27.4)
Exercise capacity in ICPET
Peak work rate (Watt) 36.0 (13.5) 34.0 (9.7)
Peak V
•








Angina pectoris 2 0
PVC 0 1
Data are presented as means (SD) unless otherwise stated. BMI Body mass
index, DLco Carbon monoxide diffusing capacity, FEV1 Forced Expiratory
Volume in one second, FVC Forced Vital Capacity, IC Inspiratory Capacity, ICPET
Incremental Cardiopulmonary Exercise Test, ICS Inhaled Corticosteroids, LABA
Long-Acting β2-Agonist, LAMA Long-Acting Muscarinic Antagonist, PVC
Premature Ventricular Contraction, SAMA Short-Acting Muscarinic Antagonist,
VC Vital Capacity. * The groups shown represent all treated patients.
Medications were not mutually exclusive, and data are presented separately.
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Dual energy x-ray absorptiometry (DEXA) was performed
to assess total body composition, including lean body
mass before and after ghrelin or placebo administration
with PR, as previously described [16].
Respiratory and peripheral muscle strength
The maximal inspiratory pressure (MIP) and maximal
expiratory pressure (MEP) were measured, as described
previously [16].
Sample size
The main multicenter study’s target sample size was 60
in the original protocol at the time of study design [16].
Before the main multicenter study ended, the power and
sample size calculations were repeated using the estimated
effect of only ghrelin treatment for improving 6-min walk
distance (6-MWD), which was based on information from
the pilot study [15,16]. The recalculated sample size was 18
in the main multicenter trial. What constituted a clinically
important change in peak V
•
o2 after ghrelin treatment with
PR was not known before the study ended. Therefore, a
formal power calculation could not be done. As an
exploratory study, it was confirmed that the number of
patients that had completed the study in our center
exceeded the number necessary for the re-calculated
sample size of 18, though the calculation was not based
on the primary outcome in the present study.
Data analysis
Two measurement points were used for evaluations of
exercise parameters: iso-time and peak exercise point.
“iso-time” was defined as the highest equivalent exercise
time achieved during the CPETs performed at pre-
treatment and Week 3 by a given subject. To obtain
“iso-time” during exercise, the values of the cardio-
respiratory parameters were calculated by linear
interpolation between adjacent measurement points for
each subject [20,21]. The absolute values of the
cardio-respiratory parameters were obtained during
CPET at 2-min intervals, and at end-exercise.
Statistical analysis
All data are expressed as means ± SD unless otherwise
indicated. Comparisons of baseline characteristics
between the groups were made by Fisher’s exact
tests and Wilcoxon rank sum tests. Effects were examined
once, at Week 3 soon after 3-week treatment. The results
at Week 3 were compared with the pre-treatment results
within each group, and between the two groups using
paired t-tests and unpaired t-tests, respectively. To assess
the time-course efficacy of ghrelin versus placebo, post-
treatment data were also analyzed using repeated-measuresanalysis of variance (ANOVA). Spearman’s rank correlation
coefficients were used to assess the relationships between
the increase in the peak V
•
o2 and other measurements.
The statistical analysis of the present study was performed
by Mr. K. Tsuguchi (Nihon Ultmarc Inc. Tokyo, Japan)
who had no relevant conflicts of interest. A p value <0.05
was considered significant (SAS 9.1.3, SAS Institute Inc.,
Cary, NC, USA).Results
A total of 20 underweight patients (mean BMI (SD),
18.3 (2.3) kg/m2) was randomized to ghrelin treatment
with PR (ghrelin group; n = 10) or placebo treatment
with PR (placebo group; n = 10), and all patients
completed the study protocol. There were no significant
differences in baseline characteristics between the
two groups (Table 1). No significant difference in the
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ghrelin group, 6970 ± 6169 watt·min versus placebo
group, 7167 ± 4310 watt·min, between-group p = 0.935)
was observed. Next, the effects of ghrelin administration
on exercise capacity, as well as the underlying
mechanisms were examined once (Week 3) using
two measurement points: iso-time and the peak exercise
point.Peak incremental exercise responses
The distribution of reasons for stopping exercise was not
different after ghrelin than after placebo; most subjects in
both groups stopped primarily because of dyspnea or a
combination of dyspnea and leg discomfort (ghrelin
group, 80% versus placebo group, 60%), and fewer subjects
stopped because of leg discomfort (ghrelin group, 20%
versus placebo group, 40%). The ghrelin-PR combination
substantially increased the peak V
•
o2 (mean difference
(ghrelin minus placebo), i.e., treatment effect = 1.2 mL/
kg/min, 95% CI: 0.2 to 2.3 mL/kg/min, between-group
p = 0.025, Table 2 and Figure 2A, or as an alternative
description, treatment effect = 60.5 mL/kg, 95% CI:
10.5 to 110.5 mL/kg, between-group p = 0.020).
Additionally, repeated-measures analysis of variance
(ANOVA) indicated a significant time-course effect
of ghrelin versus placebo in the peak V
•
o2 (p = 0.025).Table 2 Changes in peak incremental exercise parameters aft
Ghrelin, n = 10
Pre-treatment Mean D. Pre-tr
V
•
o2 mL=kg=minð Þ 13.3 (3.7) 1.4 (0.8)*** 13.4 (3
V
•
o2 mL=minð Þ 640.3 (212.5) 69.4 (45.9) 616.8
Endurance time (s) 389 (157) 48 (96) 372 (1
Dyspnea (Borg) 7.4 (1.5) −0.5 (1.3) 7.2 (1.
Leg discomfort (Borg) 5.5 (2.7) −0.8 (1.8) 6.3 (2.
VT (L) 0.97 (0.17) 0.10 (0.08)
** 1.05 (0
f (breaths/min) 34 (7) −2 (3) 28 (5)
V
•
E L=minð Þ 31.9 (6.0) 1.5 (2.7) 29.2 (6












co2 51.0 (13.6) −3.8 (3.9)
* 45.3 (7
Pao2 (mmHg) 64.4 (16.0) −0.5 (4.2) 66.1 (1
Paco2 (mmHg) 42.7 (7.0) −0.3 (2.3) 42.4 (4
HR (beats/min) 118 (14) 2 (8) 113 (1
V
•
o2=HR mL=beatsð Þ 5.4 (1.5) 0.5 (0.5)* 5.5 (1.
Plasma LT (mg/dL) 32.3 (11.8) 3.3 (7.6) 35.0 (1
Plasma NE (ng/mL) 2.45 (1.70) −0.08 (1.29) 2.65 (1
Data are presented as means (SD) unless otherwise indicated. D Difference from pr
Plasma norepinephrine level, Paco2 Arterial carbon dioxide tension, Pao2 Arterial ox
physiologic dead space/tidal volume ratio, V
•
E Minute ventilation, V
•
o2 oxygen uptak
treatment and post-treatment (within-group difference) by paired t-test. † change bAfter ghrelin-PR combination treatment, the peak V
•
o2
increased by >2 mL/kg/min in two patients and
decreased in none. Furthermore, compared with pla-
cebo, the ghrelin-PR combination significantly increased
V
•
o2=HR (treatment effect = 0.7 mL/beat, 95% CI: 0.3
to 1.2 mL/beat, between-group p = 0.003) and
decreased VD/VT (treatment effect = −0.04, 95% CI: -0.08





effect = −4.1, 95% CI: -8.2 to −0.1, between-group:




o2 (treatment effect = −4.2,
95% CI: -7.9 to −0.5, between-group: p = 0.030), but
maintained the dyspnea rating unchanged (Table 2
and Figure 2B-2D).Iso-time responses with incremental exercise
The ghrelin-PR combination significantly decreased the
dyspnea score from baseline, but not compared to placebo
(Table 3). The ghrelin-PR combination decreased VD/VT
compared to placebo (treatment effect = −0.04, 95%





o2 (within group: p < 0.05), and increased VT
(within-group: p < 0.01), with a resultant decrease in
the respiratory frequency (f ) (within-group p < 0.05)
(Table 3). The ghrelin-PR combination did not inhibit
plasma norepinephrine levels.er pulmonary rehabilitation with ghrelin or placebo
Placebo, n = 10 Treatment effect (95% CI; p value†)
eatment Mean D.
.2) 0.2 (1.3) 1.2 (0.2 to 2.3; 0.025)
(138.8) 8.9 (59.7) 60.5 (10.5 to 110.5; 0.020)
31) 59 (60)* −12 (−87 to 63; 0.749)
6) −0.9 (1.8) 0.4 (−1.1 to 1.9; 0.572)
5) −0.6 (1.7) −0.2 (−1.9 to 1.5; 0.803)
.12) 0.07 (0.23) 0.03 (−0.13 to 0.19; 0.694)
−1 (6) −1 (−5 to 4; 0.802)
.4) 0.5 (2.2) 1.0 (−1.3 to 3.3; 0.389)
.05) 0.00 (0.04) −0.04 (−0.08 to −0.00; 0.041)
.2) 0.5 (4.2) −4.2 (−7.9 to −0.5; 0.030)
.5) 0.4 (4.6) −4.1 (−8.2 to −0.1; 0.045)
1.9) −2.2 (5.4) 1.7 (−2.9 to 6.2; 0.454)
.2) 0.7 (3.0) −0.9 (−3.4 to 1.6; 0.453)
3) 7 (7)* −6 (−13 to 2; 0.115)
1) −0.2 (0.5) 0.7 (0.3 to 1.2; 0.003)
4.5) 2.5 (9.8) 0.9 (−7.4 to 9.1; 0.824)
.80) −0.11 (0.84) 0.03 (−0.99 to 1.06; 0.945)
e-treatment, f breathing frequency, HR Heart Rate, LT Plasma Lactate level, NE
ygen tension, Treatment effect, Mean difference (ghrelin minus placebo), VD/VT
e, VT Tidal volume. * p < 0.05, ** p < 0.01, *** p < 0.001: change between pre-
etween pre-treatment and post-treatment (treatment effect) by unpaired t-test.
Figure 2 With incremental exercise, cardiopulmonary parameters at peak exercise before and after 3-week administration of ghrelin or
placebo with PR. Solid symbols, ghrelin; Open symbols, placebo. Data are presented as means ± SD. * p < 0.05, ** p < 0.01: change between
pre-treatment and post-treatment (between ghrelin and placebo group difference, treatment effect) by unpaired t-test: † p < 0.05, †† p < 0.01:
repeated-measures ANOVA indicates significant time-course effects of ghrelin versus placebo. V
•
o2, oxygen uptake; VD/VT, physiologic dead space/
tidal volume ratio, V
•
E, minute ventilation; VT, tidal volume.
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load exercise
The ghrelin-PR combination significantly increased IC at
the iso-time point (within-group p < 0.05) and peak
exercise (within-group p < 0.05), though the treatment
effect compared with placebo was not significant.Correlates of improvement
The intra-subject increase in the peak V
•
o2 after ghrelin
treatment correlated with the plasma acyl-ghrelin levelTable 3 Changes in iso-time parameters during incremental e
or placebo
Ghrelin, n = 10
Pre-treatment Mean D. Pre-tr
V
•
o2 mL=kg=minð Þ 13.2 (3.7) 0.5 (1.8) 13.4 (3
Dyspnea (Borg) 7.2 (1.5) −2.0 (2.6)* 7.0 (1.7
Leg discomfort (Borg) 5.4 (2.7) −1.9 (2.9) 6.2 (2.6
VT (L) 0.97 (0.16) 0.10 (0.08)
** 1.06 (0
f (breaths/min) 34 (7) −4 (6)* 28 (5)
V
•
E L=minð Þ 31.8 (6.1) −0.4 (4.6) 29.2 (6












co2 51.1 (13.7) −2.7 (5.3) 45.2 (7
Pao2 (mmHg) 64.5 (16.0) 1.0 (5.4) 66.2 (1
Paco2 (mmHg) 42.6 (6.9) −1.1 (2.4) 42.4 (4
HR (beats/min) 118 (14) −2 (9) 113 (1
V
•
o2=HR mL=beatsð Þ 5.4 (1.5) 0.2 (0.8) 5.5 (1.1
Plasma LT (mg/dL) 32.1 (11.8) −0.3 (8.3) 34.9 (1
Plasma NE (ng/mL) 2.44 (1.71) −0.37 (1.40) 2.64 (1
Data are presented as means (SD) unless otherwise indicated. D, Difference from pr
NE, Plasma Norepinephrine level; Paco2, Arterial carbon dioxide tension; Pao2, Arteri
VD/VT, Physiologic dead space/tidal volume ratio; V
•
E Minute ventilation, V
•
o2 Oxygen
treatment and post-treatment (within-group difference) by paired t-test. † change bafter treatment (r = −0.797, p = 0.006), which in turn
correlated with the increase induced by treatment in the
plasma acyl-ghrelin level (r = −0.684, p = 0.029) and
minute ventilation ðV•EÞ (r = 0.657, p = 0.039).Discussion
This substudy of a multicenter, randomized, double-blind,
placebo-controlled trial of ghrelin treatment in under-
weight COPD patients was designed and powered to
investigate the effects of repeated ghrelin administrationxercise after pulmonary rehabilitation with ghrelin
Placebo, n = 10 Treatment effect (95% CI; p value†)
eatment Mean D.
.2) −0.8 (1.1) 1.2 (−0.2 to 2.6; 0.085)
) −2.7 (3.2)* 0.7 (−2.1 to 3.4; 0.606)
) −3.0 (2.9)* 1.1 (−1.6 to 3.9; 0.399)
.12) 0.09 (0.24) 0.01 (−0.15 to 0.18; 0.876)
−3 (8) −1 (−8 to 5; 0.658)
.5) −1.6 (3.6) 1.2 (−2.6 to 5.1; 0.510)
.05) 0.01 (0.04) −0.04 (−0.08 to −0.00; 0.048)
.2) 0.2 (4.9) −3.5 (−7.6 to 0.5; 0.086)
.5) 0.9 (5.2) −3.6 (−8.6 to 1.4; 0.149)
1.8) −1.1 (4.8) 2.1 (−2.7 to 7.0; 0.361)
.2) 0.0 (3.1) −1.2 (−3.8 to 1.4; 0.359)
3) 2 (6) −4 (−11 to 4; 0.290)
) −0.3 (0.4)* 0.5 (−0.1 to 1.1; 0.093)
4.6) −3.5 (7.9) 3.2 (−4.4 to 10.8; 0.920)
.81) −0.77 (1.06)* 0.40 (−0.77 to 1.56; 0.426)
e-treatment; f, breathing frequency; HR, Heart Rate; LT, Plasma Lactate level;
al oxygen tension; Treatment effect, Mean difference (ghrelin minus placebo);
uptake; VT, Tidal volume. * p < 0.05, ** p < 0.01: change between pre-
etween pre-treatment and post-treatment (treatment effect) by unpaired t-test.
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exercise testing. The main findings were as follows. 1)
With incremental exercise, in the ghrelin group, the
mean change from pre-treatment i) in peak V
•
o2 was sig-
nificantly increased compared with the placebo group,
and ii) that in dyspnea intensity showed a significant
within-group decrease at the iso-time point.









o2 , and VD/VT were significantly
improved compared with the placebo group at peak
exercise; iv) the mean change from pre-treatment in VT
showed a significant within-group increase at peak
exercise; and v) that in O2-pulse was increased compared
with the placebo group at peak exercise. 2) With constant-
load exercise, in the ghrelin group, the mean change from
pre-treatment in IC showed a significant within-group
increase throughout exercise.
Many approaches to treating cachectic COPD have
been attempted [2,7]. In the present study, exercise
training alone did not show significant improvements in
exertional capacity and cardio-ventilatory parameters,
except for endurance time. In the placebo group, V
•
o2
(mean difference: -0.8 mL/kg/min, within-group: p = 0.051)
and O2-pulse were not improved at the iso-time point
(Table 3). The plasma norepinephrine levels seemed to be
inhibited at the iso-time point (Table 3). Given the
reported negative connotations of sympathetic activation
in cardiac as well as respiratory disease patients [22-26],
sympathetic inhibition may have positive consequences in
COPD. These findings suggest that underweight patients
with COPD who undergo exercise training can only
increase their endurance time, efficiently decreasing V
•
o2Table 4 Changes in pre-treatment resting parameters during
Ghrelin, n = 10
Pre-treatment Mean D. Pre-tr
Body weight (kg) 48.2 (7.4) −0.1 (1.0) 46.8 (7
Total lean mass (kg) 37.2 (5.6) 0.1 (2.3) 35.5 (4
MEP‡ (cmH20) 77.7 (28.7) 16.2 (15.8) 87.2 (2
MIP‡ (cmH20) −52.7 (20.8) −10.0 (24.6) −54.2
PFT
FEV1 (L) 0.83 (0.21) 0.06 (0.16) 0.82 (0
FEV1/FVC (%) 41.7 (7.6) −1.9 (3.6) 42.4 (8
%FEV1 (%) 32.0 (9.4) 2.1 (6.3) 33.3 (1
VC (L) 2.54 (0.42) 0.18 (0.28) 2.62 (0
%VC (%) 79.6 (11.0) 5.5 (8.9) 86.1 (1
DLco (%) 61.3 (23.8) 10.0 (37.5) 72.4 (2
Data are presented as means (SD) unless otherwise indicated. D Difference from pr
Volume in one second, FVC Forced Vital Capacity, MEP Maximal Expiratory Pressure,
effect Mean Difference (ghrelin minus placebo), VC Vital Capacity. * p < 0.05, *** p <
difference) by paired t-test. † change between pre-treatment and post-treatment (tr
pre-treatment and 4 weeks after the completion of the combination treatment.and plasma norepinephrine levels. In contrast, repeated
ghrelin administration was associated with a significant
increase from pre-treatment in the peak V
•
o2 by an average
of 1.4 mL/kg/min (between-group p = 0.025, Table 2
and Figure 2A). Endurance time was not increased
after ghrelin-PR combination treatment (Table 2). These
findings suggest that patients treated with ghrelin had
a high exercise capacity with instantaneous force,
though the pedal revolutions per minute on the electrically
braked-cycle ergometer were not monitored. We consid-
ered the following potential mechanisms for the increase in
exercise capacity that was induced by ghrelin treatment: i)
improved ventilatory efficiency and ventilatory volume;
and ii) increased cardiac function.
The two major contributing factors leading to exercise
limitation in COPD may be the increased ventilatory
requirement and the decreased ventilatory capacity [27].









which are useful to estimate wasted ventilation, were
significantly decreased at peak exercise (Table 2, Figure 2B
and C), resulting in a decreased ventilatory requirement.
These findings suggest that ghrelin treatment was associ-
ated with an improvement of ventilatory efficiency at peak
exercise. VT during incremental exercise (Tables 2 and 3)
and IC during constant-load exercise were increased after
ghrelin-PR combination treatment, though the difference
compared with placebo was not significant. Additionally,
increased peak V
•
o2 after ghrelin treatment was positively
correlated with the change in V
•
E from pre-treatment. In
the present study, 4 weeks after the completion of ghrelin
and PR treatment, MEP was better in the ghrelin group
than in the placebo group (Table 4). These findingspulmonary rehabilitation with ghrelin or placebo
Placebo, n = 10 Treatment effect (95% CI; p value†)
eatment Mean D.
.6) 0.1 (1.3) −0.2 (−1.3 to 0.9; 0.698)
.7) 0.6 (0.8) −0.5 (−2.1 to 1.2; 0.561)
5.6) −6.6 (13.4) 22.8 (7.1 to 38.4; 0.007)
(15.4) −7.9 (5.4) −2.1 (−22.5 to 18.2; 0.825)
.23) 0.07 (0.16) −0.01 (−0.16 to 0.13; 0.845)
.0) −3.4 (3.8)* 1.5 (−2.1 to 5.0; 0.383)
0.5) 2.9 (6.3) −0.8 (−6.8 to 5.1; 0.778)
.50) 0.15 (0.20)* 0.03 (−0.20 to 0.26; 0.800)
5.3) 4.9 (7.3) 0.6 (−7.1 to 8.2; 0.877)
7.4) −6.1 (12.2) 16.1 (−10.1 to 42.3; 0.222)
e-treatment, DLco Carbon monoxide diffusing capacity, FEV1 Forced Expiratory
MIP Maximal Inspiratory Pressure, PFT Pulmonary Function Test, Treatment
0.001: change between pre-treatment and post-treatment (within-group
eatment effect) by unpaired t-test. ‡ MEP and MIP were tested at
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may occur through the mechanism by which ghrelin
improved respiratory muscle strength [16]. On the other
hand, ghrelin may have additional beneficial effects within
the cardiovascular system in underweight COPD patients.
Earlier studies showed that ghrelin improved cardiac
function in normal subjects and in patients/animals with
heart failure [13,28,29]. In the ghrelin group, the O2-pulse
after treatment increased significantly compared with
placebo at peak incremental exercise. Furthermore, a
recent study demonstrated that ghrelin acts on the central
nervous system to attenuate sympathetic nervous activity
[14], though in the present study, as well as in the
main study, ghrelin treatment did not show significant
sympathetic inhibition compared with placebo. Further
studies are needed to confirm the clinical significance
such as regulating exertional dyspnea. Nevertheless, we
believe that these improvements in cardio-ventilatory
parameters could represent the effect of ghrelin.
It should be noted that individuals in this study had
different reactions to PR or ghrelin therapy. Of note, in
the present study, the exercise capacity improvement by
exogenous ghrelin was negatively correlated with the
increase in the plasma acyl-ghrelin level after treatment
(r = −0.684). Since the half-life of exogenous ghrelin,
which was administered on the day before blood
sampling, was about 20 min [30], it is highly possible that
the measured plasma acyl-ghrelin level was unaffected by
the administered exogenous ghrelin, and reflected the
endogenous acyl-ghrelin. These correlations may stand to
reason, given that ghrelin administration is considered as
replacement therapy for underweight COPD patients
who may be unable to compensate for the anabolic-
catabolic imbalance, resulting in increasing the endogen-
ous plasma acyl-ghrelin levels, thought repeated exogenous
ghrelin might inhibit ghrelin production [31]. Mean-
while, as an effective adjunctive therapy, we used ex-
ercise training as a part of PR, which is well accepted
to improve exercise performance [8,32]. However, it is
important to determine whether PR improves or worsens
it, especially in underweight patients in the severe disease
stage.
This study had some limitations. First, the number of
participants was small, and few women were included in
this trial. Given the exploratory nature of the present
study, a formal power calculation was not possible. Many
statistical comparisons under exercise conditions might
increase the chance of type I error. As a consequence, the
present findings should be considered preliminary and
need to be confirmed in a future large study. Second,
ghrelin did not show any effects on whole lean body
mass and weight. The training work rate remained at
the initial setting in 4 patients (40%) in each group
during this trial, because they found the initial trainingwork rate intolerable. The lack of response to exercise
training or ghrelin treatment in weight and whole lean
body mass may be related to the inability to tolerate
the type, the intensity, and/or the duration of the exer-
cise training. Third, there was a significant difference
between the ghrelin and placebo groups in the peak V
•
o2
measured by the protocol of 2-min increments to 10 W
in the present study. However, in the main multicenter
trial at Week 3, outcome measurements measured with
a continuous ramp rate of 5 W/min showed no
improvements with ghrelin compared to placebo [16].
In the present study, in the ghrelin group, the mean
change from pre-treatment in the peak V
•
o2 measured
by the protocol of 2-min increments to 10 W was larger
than that measured by the protocol with the ramp rate
of 5 W/min (mean difference: by 2-min increments
to 10 W, 1.4 mL/kg/min versus with a ramp rate of
5 W/min, 1.1 mL/kg/min). See Table E1 in Additional
file 2 (Supplementary Results) for other details.
Several investigators have suggested the desirability
of adjusting the work rate increment in exercise test-
ing according to the patient’s cardiopulmonary condi-
tion [33,34]. Tests in which the work rate increased
too rapidly may not allow sufficient data for the
evaluation to be accumulated. A more suitable exercise
testing protocol, considering the patient’s cardiopulmo-
nary condition, should have been conducted in the main
multicenter trial. Also, in the present study, at Week 7,
i.e., 4 weeks after the completion of the treatment,
CPET should have been conducted to evaluate the
sustained effects of ghrelin treatment, as shown in the
multicenter trial [16].Conclusion
Given the short-term nature of the study and the
discrepancy between the physiological findings and
the measures of direct patients benefit, the present
findings need to be confirmed by further study.
However, in the present substudy, ghrelin administra-
tion was associated with improved exertional capacity
and improvements in cardio-ventilatory parameters,
although the main multicenter study showed no
significant difference between the ghrelin and placebo
group in exercise capacity. Development of ghrelin
administration as a novel cachexia-targeted therapy
capable of improving exercise performance may be
helpful in COPD treatment.
Additional files
Additional file 1: Effects of Ghrelin Treatment on Exercise Capacity in
Underweight COPD Patients: a substudy of a multicenter, randomized,
double-blind, placebo-controlled trial of ghrelin treatment.
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